Trials | Multicentre trial | Induction | mTOR-I group | MPA group | Follow-up (years) | ||||
---|---|---|---|---|---|---|---|---|---|
Country | No.(male) | Maintenance | Dose/target level | Maintenance | Dose/target level | ||||
Vitko et al. 2005 | Multiple | Yes | 588 (380) | None | EVE + CsA + ST | 1.5 mg/d | MMF + CsA + ST | 2 g/d | 3 |
3 mg/d | |||||||||
Lorber et al. 2005 | Multiple | Yes | 583 (365) | Bas | EVE + RD-CsA + ST | 1.5 mg/d | MMF + CsA + ST | 2 g/d | 3 |
3 mg/d | |||||||||
Mendez et al. 2005 | America | Yes | 361 (246) | None | SRL + TAC + ST | 2 mg/d | MMF + TAC + ST | 2 g/d | 1 |
Vitko et al. 2006 | Multiple | Yes | 977 (624) | None | SRL + TAC + ST | 0.5 mg/d | MMF + TAC + ST | 1 g/d | 0.5 |
2 mg/d | |||||||||
Kumar et al. 2008 | America | No | 200 (140) | Bas | SRL + TAC | 5-10 ng/ml | MMF + TAC | 1-3 u/ml | 5 |
SRL + CsA | 5-10 ng/ml | MMF + CsA | 1-3 u/ml | ||||||
Sampaio et al. 2008 | Brazil | Yes | 100 (69) | None | SRL + TAC + ST | 2 mg/d | MMF + TAC + ST | 2 g/d | 1 |
Gurp et al. 2010 | Multiple | Yes | 634 (408) | None | SRL + RD-TAC + ST | 1 mg/d | MMF + TAC + ST | 1 mg/d | 0.5 |
Guerra et al. 2011 | America | No | 150 (99) | Dac | SRL + TAC + ST | 6-10 ng/ml | MMF + TAC + ST | 2 g/d | 8 |
SRL + CsA + ST | 6-10 ng/ml | ||||||||
Chhabra et al. 2012 | America | No | 82 (50) | Bas | SRL + TAC | 7-10 ng/ml | MMF + TAC | 2 g/d | 8.5 |
Crbrik et al. 2013 | Multiple | Yes | 833 (557) | Bas | EVE + RD-CsA ± ST | 1.5 mg/d | Ec-MPS + CsA ± ST | 1.44 g/d | 2 |
3 mg/d | |||||||||
Takahashi 2013 | Japan | Yes | 122 (83) | Bas | EVE + RD-CsA + ST | 3-8 ng/ml | MMF + CsA + ST | 2 g/d | 1 |